What Is Tesofensine? Benefits, Research & Safety

Tesofensine was developed by NeuroSearch A/S, a Danish pharmaceutical company specialising in central nervous system drugs. The compound was originally designed as a treatment for Parkinson's disease and Alzheimer's disease based on its ability to enhance monoaminergic neurotransmission. Phase II trials for Parkinson's disease in the early 2000s did not demonstrate sufficient efficacy for this indication. However, researchers observed that trial participants experienced significant weight loss—an unexpected finding that prompted investigation of tesofensine for obesity treatment. The TIPO-1 and TIPO-2 Phase II obesity trials, published around 2008-2010, showed remarkable weight loss results. At the 0.5 mg dose, participants lost an average of 12.8 kg (approximately 13% of body weight) over 24 weeks—unprecedented results for a weight loss drug. However, the trials also revealed dose-dependent increases in heart rate (7-8 beats per minute at the 0.5 mg dose), raising cardiovascular safety concerns that complicated regulatory path forward. NeuroSearch later licensed tesofensine to Saniona, which continued development at lower doses aimed at achieving a better benefit-risk profile. The compound remains in clinical development but has not achieved regulatory approval.